secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2025-10-07T23:59:59+00:00
Accession:  0001104659-25-097317
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax completes Nuvaxovid EU marketing authorization transfer to Sanofi; triggers $25M milestone
--------------------------------------------------------------------------------

- European Commission approved transfer of Nuvaxovid EU marketing authorization from Novavax CZ to Sanofi Winthrop Industrie.
- Milestone payment of $25M triggered; Novavax expects receipt in Q1 2026.
- Additional milestones: $25M for U.S. transfer, $75M for technology transfer, up to $350M for combo products.
- Novavax eligible for tiered royalties on Sanofi's standalone COVID vaccine and combination products.
- CEO John Jacobs: successful transfer is another step in ensuring global access to protein-based COVID vaccine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925097317/0001104659-25-097317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925097317/tm2528134d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-097317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer